In our earlier work, we reported highly sensitive detection of EGFR mutations (T790M and L868R) in microfluidically enriched CTCs, which showed a complete concordance of mutation status with matched primary tumors in non-small-cell lung cancer (NSCLC) patients [44]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.